LEO Science & Tech Hub: A New Model for Cross-Industry Innovation

article image
ARTICLE SUMMARY:

To realize its goal of accessing external innovation, LEO Pharma faces several challenges; it’s focused solely on dermatology, and as a mid-sized specialty pharma, it has to be choosy about the acquisitions it makes. It’s addressing those challenges through its Cambridge-based LEO Science & Tech Hub, which aims to be the partner of choice for medtech innovators.

Pharmaceutical and medical device companies are aware that beyond a certain relatively small size, their bulk, culture, and the dictates of their commercial mandate stymie innovation. For the past two decades, most of their innovation has tended to come from the acquisition of start-ups that can operate more nimbly to bring novel science and inventions forward.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.


Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite

Questions?

We're here to help! Please contact us at: